Privia Health Group, Inc. (PRVA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
31/58
2.7 / 5 stars
All 58 Win/Lose results and 62 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 10 wins, 2 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinPRVA / S&P 25.09% / 15.20% |
WinPRVA / S&P 24.10% / 15.00% |
WinPRVA / S&P 90.91% / 50.40% |
| 2026-Q12/3 |
LosePRVA / S&P -13.24% / -4.33% |
WinPRVA / S&P 24.72% / 11.30% |
WinPRVA / S&P 33.33% / 27.70% |
| 2025-Q42/3 |
LosePRVA / S&P -4.78% / 2.65% |
WinPRVA / S&P 22.26% / 9.00% |
WinPRVA / S&P 54.55% / 13.40% |
| 2025-Q33/3 |
WinPRVA / S&P 8.26% / 8.12% |
WinPRVA / S&P 19.01% / 4.61% |
WinPRVA / S&P 18.18% / 13.45% |
| 2025-Q21/3 |
LosePRVA / S&P 2.45% / 10.94% |
WinPRVA / S&P 12.05% / 4.83% |
LosePRVA / S&P -15.38% / 10.63% |
| 2025-Q12/3 |
WinPRVA / S&P 14.83% / -4.27% |
WinPRVA / S&P 6.79% / 4.98% |
LosePRVA / S&P -25.00% / 10.57% |
| 2024-Q41/3 |
WinPRVA / S&P 7.36% / 2.41% |
LosePRVA / S&P 4.74% / 5.25% |
LosePRVA / S&P -45.00% / 6.15% |
| 2024-Q31/3 |
LosePRVA / S&P 4.78% / 5.89% |
WinPRVA / S&P 8.54% / 5.89% |
LosePRVA / S&P -66.67% / 6.11% |
| 2024-Q21/3 |
LosePRVA / S&P -11.28% / 4.28% |
WinPRVA / S&P 12.52% / 5.38% |
LosePRVA / S&P -55.17% / 5.12% |
| 2024-Q12/3 |
LosePRVA / S&P -14.94% / 10.56% |
WinPRVA / S&P 18.02% / 5.71% |
WinPRVA / S&P 23.08% / 5.59% |
| 2023-Q41/3 |
LosePRVA / S&P 0.13% / 11.69% |
WinPRVA / S&P 22.19% / 6.81% |
LosePRVA / S&P -322.22% / 7.78% |
| 2023-Q31/3 |
LosePRVA / S&P -11.91% / -3.27% |
WinPRVA / S&P 24.75% / 7.52% |
LosePRVA / S&P -197.06% / -5.03% |
| 2023-Q21/3 |
LosePRVA / S&P -5.43% / 8.74% |
WinPRVA / S&P 28.12% / 9.50% |
LosePRVA / S&P -165.91% / -8.57% |
| 2023-Q12/3 |
WinPRVA / S&P 21.58% / 7.50% |
WinPRVA / S&P 34.01% / 10.77% |
LosePRVA / S&P -106.44% / -15.69% |
| 2022-Q41/3 |
LosePRVA / S&P -33.32% / 7.56% |
WinPRVA / S&P 40.41% / 11.88% |
LosePRVA / S&P -95.00% / -17.99% |
| 2022-Q32/3 |
WinPRVA / S&P 16.96% / -4.88% |
WinPRVA / S&P 40.13% / 13.47% |
LosePRVA / S&P -79.64% / -1.41% |
| 2022-Q22/3 |
WinPRVA / S&P 8.94% / -16.10% |
WinPRVA / S&P 36.73% / 13.71% |
LosePRVA / S&P -68.79% / 11.04% |
| 2022-Q12/3 |
WinPRVA / S&P 3.32% / -4.60% |
WinPRVA / S&P 30.41% / 15.97% |
LosePRVA / S&P -712.12% / 42.23% |
| 2021-Q41/3 |
LosePRVA / S&P 9.80% / 11.03% |
WinPRVA / S&P 18.25% / 15.00% |
LosePRVA / S&P -645.45% / 96.40% |
| 2021-Q30/1 |
LosePRVA / S&P -46.90% / 0.58% |
No dataPRVA / S&P / 10.77% |
No dataPRVA / S&P / 69.42% |
| 2021-Q20/0 |
No dataPRVA / S&P / 8.55% |
No dataPRVA / S&P / 6.58% |
No dataPRVA / S&P / 51.81% |
| 2021-Q10/0 |
No dataPRVA / S&P / 6.17% |
No dataPRVA / S&P / -1.06% |
No dataPRVA / S&P / 7.39% |
| 2020-Q40/0 |
No dataPRVA / S&P / 12.15% |
No dataPRVA / S&P / -3.72% |
No dataPRVA / S&P / -33.42% |
| 2020-Q30/0 |
No dataPRVA / S&P / 8.93% |
No dataPRVA / S&P / -2.04% |
No dataPRVA / S&P / -27.10% |
| 2020-Q20/0 |
No dataPRVA / S&P / 20.54% |
No dataPRVA / S&P / -0.46% |
No dataPRVA / S&P / -27.11% |
| 2020-Q10/0 |
No dataPRVA / S&P / -19.60% |
No dataPRVA / S&P / 3.47% |
No dataPRVA / S&P / -14.75% |
| 2019-Q40/0 |
No dataPRVA / S&P / 9.07% |
No dataPRVA / S&P / 5.36% |
No dataPRVA / S&P / 2.99% |
| 2019-Q30/0 |
No dataPRVA / S&P / 1.70% |
No dataPRVA / S&P / 5.02% |
No dataPRVA / S&P / 0.21% |
| 2019-Q20/0 |
No dataPRVA / S&P / 4.30% |
No dataPRVA / S&P / 6.64% |
No dataPRVA / S&P / 8.65% |
| 2019-Q10/0 |
No dataPRVA / S&P / 13.65% |
No dataPRVA / S&P / 8.12% |
No dataPRVA / S&P / 14.29% |
| 2018-Q40/0 |
No dataPRVA / S&P / -13.52% |
No dataPRVA / S&P / 9.05% |
No dataPRVA / S&P / 18.23% |
| 2018-Q30/0 |
No dataPRVA / S&P / 7.71% |
No dataPRVA / S&P / 10.21% |
No dataPRVA / S&P / 19.06% |
| 2018-Q20/0 |
No dataPRVA / S&P / 3.43% |
No dataPRVA / S&P / 9.03% |
No dataPRVA / S&P / 14.46% |
| 2018-Q10/0 |
No dataPRVA / S&P / -0.76% |
No dataPRVA / S&P / 7.68% |
No dataPRVA / S&P / 12.46% |
| 2017-Q40/0 |
No dataPRVA / S&P / 6.64% |
No dataPRVA / S&P / 7.03% |
No dataPRVA / S&P / 13.82% |
| 2017-Q30/0 |
No dataPRVA / S&P / 4.48% |
No dataPRVA / S&P / 5.68% |
No dataPRVA / S&P / 17.57% |
| 2017-Q20/0 |
No dataPRVA / S&P / 3.09% |
No dataPRVA / S&P / 4.83% |
No dataPRVA / S&P / 17.74% |
| 2017-Q10/0 |
No dataPRVA / S&P / 6.07% |
No dataPRVA / S&P / 3.67% |
No dataPRVA / S&P / 13.32% |
| 2016-Q40/0 |
No dataPRVA / S&P / 3.82% |
No dataPRVA / S&P / 2.09% |
No dataPRVA / S&P / 7.05% |
| 2016-Q30/0 |
No dataPRVA / S&P / 3.85% |
No dataPRVA / S&P / 0.20% |
No dataPRVA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -9.46% | 20.78% |
| Annualized return | -9.46% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PRVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.90% | 83.14% |
| Annualized return | -6.59% | 12.86% |
10Y · 2021-04-28 to 2026-08-27
| Metric | PRVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -9.30% | 319.30% |
| Annualized return | -0.97% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |